• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过临时导管腹腔内给药α2b干扰素(IFN)治疗卵巢癌。初步数据。

Alpha 2b interferon (IFN) by intraperitoneal administration via temporary catheter in ovarian cancer. Preliminary data.

作者信息

Iaffaioli R V, Frasci G, Facchini G, Pagliarulo C, Pacelli R, Scala S, Espinosa A, Bianco A R

机构信息

Cattedra di Oncologia Medica, Università di Cagliari.

出版信息

Eur J Gynaecol Oncol. 1991;12(1):69-75.

PMID:2050163
Abstract

Thirty-nine patients with epithelial ovarian cancer admitted to the Division of Medical Oncology of the Medical School II of Naples were given 159 courses of alpha 2b interferon (30 Mil./sqm IU) intraperitoneally from October 1986 to November 1989. IFN was generally administered every three weeks, but six patients received the drug weekly at the same dose, for an additional period. In 15 patients IFN was added to standard systemic chemotherapy as first line treatment; the remaining patients, all pretreated (22 with minimal and 2 with no residual disease), received an intraperitoneal multidrug treatment combining IFN, cisplatin and mitoxantrone. Peritoneal access was achieved through a temporarily implanted 18 gauge catheter and the drug was instilled in a large fluid volume (2,000 ml) to ensure wide spread and uniform distribution. IFN was well tolerated: only one patient had to discontinue treatment because of severe fatigue. No major complication related to catheter implantation or function occurred. 3/15 untreated and 11/20 pretreated patients, evaluable for response, achieved a pathological complete response (pCR). In view of IFN's lack of significant toxicity and the safety and tolerability of a temporary small gauge catheter for peritoneal access, intraperitoneal chemotherapy including IFN should be useful in ovarian cancer patients with minimal or absent disease after first-line systemic treatment.

摘要

1986年10月至1989年11月期间,那不勒斯第二医学院医学肿瘤学部门收治的39例上皮性卵巢癌患者接受了159个疗程的α2b干扰素(3000万国际单位/平方米)腹腔内注射治疗。干扰素一般每三周给药一次,但有6例患者在额外一段时间内每周接受相同剂量的药物治疗。15例患者将干扰素作为一线治疗添加到标准全身化疗中;其余患者均接受过预处理(22例为微小残留病,2例无残留病),接受了一种将干扰素、顺铂和米托蒽醌联合的腹腔内多药治疗。通过临时植入的18号导管实现腹腔通路,药物注入大量液体(2000毫升)中以确保广泛且均匀的分布。干扰素耐受性良好:只有1例患者因严重疲劳不得不停止治疗。未发生与导管植入或功能相关的重大并发症。15例未接受过治疗和20例接受过预处理且可评估反应的患者中,3例和11例达到了病理完全缓解(pCR)。鉴于干扰素缺乏显著毒性以及临时小口径导管用于腹腔通路的安全性和耐受性,包括干扰素的腹腔内化疗对于一线全身治疗后微小残留病或无残留病的卵巢癌患者应是有用的。

相似文献

1
Alpha 2b interferon (IFN) by intraperitoneal administration via temporary catheter in ovarian cancer. Preliminary data.通过临时导管腹腔内给药α2b干扰素(IFN)治疗卵巢癌。初步数据。
Eur J Gynaecol Oncol. 1991;12(1):69-75.
2
Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study.卡铂与α-2b干扰素腹腔内联合作为微小残留卵巢癌的一线治疗:一项前瞻性研究。
Eur J Cancer. 1994;30A(7):946-50. doi: 10.1016/0959-8049(94)90120-1.
3
A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study.一项关于未经治疗的III期上皮性卵巢癌患者腹腔内注射干扰素-α 2b联合静脉注射顺铂及环磷酰胺化疗的I期研究:一项妇科肿瘤学组的初步研究。
Gynecol Oncol. 1995 Nov;59(2):267-72. doi: 10.1006/gyno.1995.0020.
4
Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.腹腔内注射人重组干扰素α-2b治疗微小残留卵巢癌。
Eur J Cancer. 1990 Mar;26(3):353-8. doi: 10.1016/0277-5379(90)90233-j.
5
Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer.卡铂联合重组干扰素α腹腔内化疗治疗卵巢癌
Eur J Gynaecol Oncol. 1994;15(6):437-42.
6
[Treatment of ovarian carcinoma with intraperitoneal administration of interferon alpha 2b].α-2b干扰素腹腔内给药治疗卵巢癌
Minerva Ginecol. 2001 Feb;53(1 Suppl 1):67-71.
7
Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer.
Ann Chir Gynaecol Suppl. 1994;208:25-7.
8
Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease.腹腔内(ip)顺铂-米托蒽醌-α-2b干扰素用于微小残留病的卵巢癌患者。
Gynecol Oncol. 1993 Jul;50(1):60-7. doi: 10.1006/gyno.1993.1165.
9
Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.高剂量α-2b干扰素与白细胞介素-2大剂量推注隔日交替给药治疗转移性肾细胞癌:一项II期研究
Cancer. 1993 Sep 1;72(5):1733-42. doi: 10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x.
10
Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer.
Cancer. 1989 Sep 1;64(5):1029-33. doi: 10.1002/1097-0142(19890901)64:5<1029::aid-cncr2820640511>3.0.co;2-#.

引用本文的文献

1
Production of a cellular product consisting of monocytes stimulated with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for human use.用于人类的由经 Sylatron(聚乙二醇干扰素 alfa-2b)和 Actimmune(干扰素 gamma-1b)刺激的单核细胞组成的细胞产品的生产。
J Transl Med. 2019 Mar 14;17(1):82. doi: 10.1186/s12967-019-1822-6.
2
Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.白细胞介素 4 假单胞菌外毒素与 IFN-α 和 IFN-γ 的联合免疫疗法在体外和人卵巢癌小鼠模型中发挥抗肿瘤作用。
Immunotherapy. 2019 Apr;11(6):483-496. doi: 10.2217/imt-2018-0158.
3
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.
Sylatron(聚乙二醇干扰素 alfa-2b)和 Actimmune(γ-干扰素)体外刺激自体单核细胞用于复发性卵巢癌腹腔内给药的 1 期临床试验。
J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5.
4
Monocyte and interferon based therapy for the treatment of ovarian cancer.基于单核细胞和干扰素的卵巢癌治疗方法。
Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15.